Drug Name: Daxxify

Active Ingredient: daxibotulinumtoixnA-lanm

Indications: To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity.

Approval Date: 9/7/2022

Company: Revance Therapeutics, Inc

Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *